Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 251

The DOI matches its Crossref record.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Open access
Kreitman, Robert J., Dearden, Claire, Zinzani, Pier Luigi, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas E., le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri A., Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn Tore, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia Arana, Saglio, Giuseppe, Roboz, Gail J., Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, Giles, Francis · 2018 · Leukemia

Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0210-1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 251

Metadata

Authors
Kreitman, R. J., Dearden, C., Zinzani, P. L., Delgado, J., Karlin, L., Robak, T., Gladstone, D. E., le Coutre, P., Dietrich, S., Gotic, M., Larratt, L., Offner, F., Schiller, G., Swords, R., Bacon, L., Bocchia, M., Bouabdallah, K., Breems, D. A., Cortelezzi, A., Dinner, S., Doubek, M., Gjertsen, B. T., Gobbi, M., Hellmann, A., Lepretre, S., Maloisel, F., Ravandi, F., Rousselot, P., Rummel, M., Siddiqi, T., Tadmor, T., Troussard, X., Yi, C. A., Saglio, G., Roboz, G. J., Balic, K., Standifer, N., He, P., Marshall, S., Wilson, W., Pastan, I., Yao, N.-S., & Giles, F.
Venue
Leukemia
Published
2018-07-20
Volume
32
Issue
8
Pages
1768-1777
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2884362356
Cited by
251
References
0
FWCI
16.81
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. https://app.cochat.ai/papers/10.1038/s41375-018-0210-1
The paper
Kreitman, R. J., Dearden, C., Zinzani, P. L., Delgado, J., Karlin, L., Robak, T., Gladstone, D. E., le Coutre, P., Dietrich, S., Gotic, M., Larratt, L., Offner, F., Schiller, G., Swords, R., Bacon, L., Bocchia, M., Bouabdallah, K., Breems, D. A., Cortelezzi, A., . . . Giles, F. (2018). Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. https://doi.org/10.1038/s41375-018-0210-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.